| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 interim results example | Phase 3 | — | Subscribe to access the data. | Biologics | Hematologic System | ||
Phase 3 interim results example | Phase 3 | — | Subscribe to access the data. | Biologics | Hematologic System | ||
Phase 3 interim results example | Phase 3 | — | Subscribe to access the data. | Biologics | Hematologic System |
Recent Updates
Recently added Catalysts
Novo Nordisk A/S$49.48
+0.61 (+1.24%)
A 86Pipeline Score Fair Value Pharma · Commercial
Market Cap
198.94 B
EPS
4.27
P/E Ratio
10.55 $
Value Trade
478.54 M
-0.97 %
Week
14.84 %
1 Month
-5.71 %
3 Month
-4.38 %
6 Month
10.33 %
5 Year
28,000 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
6.32 M
52 Week Range
35.12 - 81.44
% held by Insiders
0 %
% held by Institutions
9.78 %
Enterprise Value
218.18 B
Total Shares
3.37 B
Short %
0.73 %
Float Shares
3.37 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Novo Nordisk A/S
17Total events
0Upcoming
5Tier-1 (high impact)
2025 – 2026Coverage
Event history 17
Jul 11, 2026
◆Oral PresentationdenecimigPresentation
Oral presentation: Mim8 (denecimig) prophylaxis in adults and adolescents with haemophilia A with or without inhibitors: Interim results from the FRONTIER4 long-term safety and efficacy study
hemophilia Asource ↗
Jul 11, 2026
◆Poster PresentationdenecimigPresentation
Poster presentation: FVIIIa-mimetic bispecific antibody (Mim8) enhances thrombus formation of von Willebrand disease (VWD) under high shear flow condition
von Willebrand diseasesource ↗
Jul 11, 2026
◆Oral PresentationConcizumabPresentation
Oral presentation: Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off
hemophilia A or B with inhibitorssource ↗
Jul 11, 2026
◆Poster PresentationConcizumabPresentation
Poster presentation: Mechanism-based functional monitoring of concizumab focusing on coagulation initiation: from comprehensive global assays to TFPI-oriented assessment
Jul 11, 2026
◆Poster PresentationPresentation
Poster presentation: Real-World Indirect Cost Burden and Patient-Reported Outcomes in Adults with Hemophilia A in the United States – A CHESS-US Analysis
hemophilia Asource ↗
Q3 2026
▲Product LaunchWegovy®pillPost-Market
Planned launch of Wegovy®pill in select markets in second half of 2026
obesity or overweight with weight-related conditionsource ↗
Jun 11, 2026
▲MHRA MilestoneWegovy®pillEx-US Regulatory
MHRA approval of Wegovy®pill (semaglutide tablets) for weight management in the UK
obesity or overweight with weight-related conditionsource ↗
Jun 11, 2026
▲Full ResultsSemaglutideClinical Data
OASIS 4 topline results: semaglutide tablets 25 mg achieved ~14% weight loss vs ~2% placebo (treatment policy) and ~17% vs ~3% (on-treatment) at 64 weeks
obesity or overweight with weight-related condition without diabetessource ↗
Jun 2026
▲Product LaunchWegovy®pillPost-Market
Anticipated availability of Wegovy®pill via private prescription in the UK within weeks
obesity or overweight with weight-related conditionsource ↗
May 27, 2026
◆Oral PresentationSemaglutidePresentation
ESSENCE Menopause subgroup analysis presented at EASL 2026
MASHsource ↗
May 26, 2026
◆Oral PresentationPresentation
POSEIDON study results presented at EAS Congress
cardiovascular diseasesource ↗
Drug Pipeline Intelligence
A86
Pipeline Score $161.0B
Pipeline ValueFair Value
Valuation Signal168
Drugs Scored2.7x
rNPV / MCap Top 98%
Large Pharma (rank 19 of 911)
Percentile RankNovo Nordisk A/S earns an A-grade pipeline score (86/100), with $161.1B risk-adjusted pipeline value, led by IDegLira in Type 2 Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDegLira Small molecule | Diabetes Mellitus | Phase 3 | NCT03737240 | 58% | $15.0B | COMPLETED | 145 | - | - | Jul 8, 2022 | - | Sep 8, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
denecimig | hemophilia A | Phase 3 | 2026-06-26 | Interim results from the FRONTIER4 long-term safety and efficacy study Read More | Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig Read More | |
denecimig | hemophilia A | Phase 3 | 2026-06-26 | Interim results from the FRONTIER4 long-term safety and efficacy study Read More | Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig Read More | |
denecimig | hemophilia A | Phase 3 | 2026-06-26 | Interim results from the FRONTIER4 long-term safety and efficacy study Read More | Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NVO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NVO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NVOBrenus Pharma stärkt seine Governance durch die Ernennung eines neuen President und die Berufung einer ehemaligen EVP von Novo Nordisk als unabhängiges Mitglied
Brenus Pharma has strengthened its governance by appointing a new President and bringing in a former EVP from Novo Nordisk as an independent board member. This move aims to enhance the company's leadership and oversight. The changes reflect Brenus Pharma's commitment to improving its corporate governance structure.
Read more →NVOResumen: Brenus Pharma refuerza su gobierno corporativo con el nombramiento de un nuevo presidente y la incorporación del ex vicepresidente ejecutivo de Novo Nordisk como miembro independiente
Brenus Pharma has strengthened its corporate governance by appointing a new president and adding a former executive vice president of Novo Nordisk as an independent member. This move aims to enhance the company's leadership structure and oversight. The changes reflect Brenus Pharma's commitment to improving its governance practices.
Read more →NVORiassunto: Brenus Pharma consolida la propria governance con l'arrivo di un nuovo presidente e la nomina a membro indipendente di un ex EVP di Novo Nordisk
Brenus Pharma has strengthened its governance by appointing a new president and an independent member from Novo Nordisk. This move is expected to enhance the company's leadership and strategic direction. The changes reflect Brenus Pharma's commitment to improving its operational framework.
Read more →NVOSamenvatting: Brenus Pharma versterkt zijn bestuur met de aanstelling van een nieuwe voorzitter en de benoeming van de voormalige EVP van Novo Nordisk tot onafhankelijk lid
Brenus Pharma has strengthened its board by appointing a new chairman and naming the former EVP of Novo Nordisk as an independent member. This move is aimed at enhancing the company's governance and strategic direction. The changes reflect Brenus Pharma's commitment to leadership and expertise in the biopharma sector.
Read more →NVOBrenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member
Brenus Pharma has announced the appointment of a new president and the addition of a former executive vice president from Novo Nordisk as an independent board member. This move is aimed at strengthening the company's governance structure. The changes reflect Brenus Pharma's commitment to enhancing leadership and oversight.
Read more →NVONovo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
Novo Nordisk will present new data on its hemophilia portfolio at the ISTH Congress 2026, including findings from the FRONTIER4 study on investigational denecimig. The data will cover various dosing frequencies and age groups for hemophilia A patients. Additionally, results from the explorer10 study on concizumab will be shared, focusing on pediatric patients with inhibitors.
Read more →NVONovo Nordisk A/S - share repurchase programme
Novo Nordisk has initiated a share repurchase program, allowing for the buyback of up to DKK 15 billion worth of B shares over a 12-month period. As of June 12, 2026, the company has repurchased nearly 20 million shares, reflecting a proactive approach to enhancing shareholder value. The program is in compliance with European regulations and aims to optimize the company's capital structure.
Read more →NVONovo Nordisk A/S: IT Security incident at Novo Nordisk
Novo Nordisk A/S reported an IT security incident involving unauthorized access to some internal systems. The company has initiated an investigation with external cybersecurity experts and is coordinating with authorities. While core operations remain unaffected, some non-public personal data was copied externally. The company is taking measures to secure its systems.
Read more →NVONovo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
Novo Nordisk's Wegovy pill, an oral GLP-1 receptor agonist for weight management, has been approved in the UK. This approval is based on the OASIS 4 trial results, showing significant weight loss compared to placebo. The pill offers a daily alternative to injectable treatments for adults living with obesity or overweight. Wegovy is expected to be available via private prescription shortly.
Read more →NVONovo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
Novo Nordisk's POSEIDON study reveals that 40% of patients with cardiovascular disease have cardiovascular inflammation, which increases their risk of heart attacks and strokes. The study, involving 18,904 patients across 18 countries, underscores a significant gap in cardiovascular care, as inflammation persists despite standard treatments. These findings highlight the need for targeted therapies to address this unmet need.
Read more →NVONovo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
Novo Nordisk announced that the CHMP has recommended the approval of Wegovy® 7.2 mg in a single-dose pen for obesity treatment in the EU. The drug demonstrated a mean weight loss of 20.7% in the STEP UP trial, with one-third of participants achieving over 25% weight loss. The launch is expected in Q3 2026.
Read more →NVONovo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
Novo Nordisk's Wegovy pill, an oral semaglutide treatment, has received a positive recommendation from the CHMP for approval in the EU. This marks it as the first oral GLP-1 therapy for weight management, demonstrating a mean weight loss of 16.6%. The recommendation includes data showing its effectiveness in reducing cardiovascular risks. The launch is planned for select markets outside the US in late 2026.
Read more →NVONovo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Novo Nordisk is set to present new data on semaglutide at the EASL Congress 2026, demonstrating its effectiveness in treating metabolic dysfunction-associated steatohepatitis (MASH). The findings from the ESSENCE trial confirm semaglutide's favorable liver safety profile and its benefits for various patient subgroups, including menopausal women and Japanese populations. This highlights the urgent need for better treatment options for the largely undiagnosed MASH patient population.
Read more →NVONovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk has disclosed transactions made in its shares by board members and executives, in compliance with market abuse regulations. This announcement reflects the company's commitment to transparency in financial dealings. The report includes details on aggregated volumes and prices of the transactions, reinforcing Novo Nordisk's dedication to ethical practices.
Read more →NVOSECURITIES AND EXCHANGE COMMISSION
The article discusses the Articles of Association for Novo Nordisk A/S, detailing the company's name, objects, share capital, share issuance, and governance structure. It outlines the class structures of shares, rights of shareholders, and the procedures for increasing share capital. The document serves as a formal declaration of the company's regulatory compliance and operational guidelines. The provisions also include details about general meetings and shareholder rights.
Read more →Competitive Position
How NVO ranks across every disease it competes inCompetitive Position is a premium feature
See how NVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial